Initiate the Phase 1b cohort expansion study of COM701 with Opdivo
Deadline passed; outcome being checked
- Announced
- 22 Feb 2021
- Due
- 30 Jun 2021
- Status
- Checking
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Study initiation is expected in the second quarter of 2021.”
What we found
The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- 2 versions
-
Version 1 · original · stated 22 Feb 2021
Deadline 30 Jun 2021 (“in the second quarter of 2021”) · wording expected
-
Version 2 · stated 25 Feb 2021
Deadline 30 Jun 2021 (“in the second quarter of 2021”) · wording firm
“The study is on track to initiate in the second quarter of 2021”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 1b cohort expansion study of COM701 with Opdivo
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Partner
Tell me what happens
This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- OutcomeNot yet assessed. Nothing is judged before the deadline.
Are you Compugen Ltd.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-CGEN-024156 · Corrections policy